Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNSR NASDAQ:OBIO NASDAQ:PROF NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$5.82$5.70$5.06▼$13.47$70.45M0.8741,940 shs27,981 shsOBIOOrchestra BioMed$4.10+0.7%$4.10$2.20▼$5.42$243.71M0.5224,059 shs556,216 shsPROFProfound Medical$6.63-0.3%$6.75$3.76▼$8.95$241.65M0.7253,936 shs4,940 shsSGHTSight Sciences$5.13+7.1%$4.42$3.11▼$9.24$260.62M2.41141,280 shs155,417 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR+2.46%+3.56%-1.02%-40.91%-55.09%OBIOOrchestra BioMed+1.24%+2.01%+0.25%-3.10%+28.39%PROFProfound Medical-0.89%-2.06%-6.86%+20.69%-2.06%SGHTSight Sciences-0.62%+4.13%-2.84%+30.52%+14.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$5.82$5.70$5.06▼$13.47$70.45M0.8741,940 shs27,981 shsOBIOOrchestra BioMed$4.10+0.7%$4.10$2.20▼$5.42$243.71M0.5224,059 shs556,216 shsPROFProfound Medical$6.63-0.3%$6.75$3.76▼$8.95$241.65M0.7253,936 shs4,940 shsSGHTSight Sciences$5.13+7.1%$4.42$3.11▼$9.24$260.62M2.41141,280 shs155,417 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR+2.46%+3.56%-1.02%-40.91%-55.09%OBIOOrchestra BioMed+1.24%+2.01%+0.25%-3.10%+28.39%PROFProfound Medical-0.89%-2.06%-6.86%+20.69%-2.06%SGHTSight Sciences-0.62%+4.13%-2.84%+30.52%+14.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNSRLENSAR 2.33Hold$10.0071.82% UpsideOBIOOrchestra BioMed 2.57Moderate Buy$13.60231.71% UpsidePROFProfound Medical 2.00Hold$12.0081.00% UpsideSGHTSight Sciences 2.44Hold$8.1458.75% UpsideCurrent Analyst Ratings BreakdownLatest LNSR, SGHT, PROF, and OBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026SGHTSight Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$4.35 ➝ $5.155/22/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026OBIOOrchestra BioMed B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.005/14/2026OBIOOrchestra BioMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026OBIOOrchestra BioMed BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $13.005/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/11/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNSRLENSAR$58.44M1.21N/AN/A($2.18) per share-2.67OBIOOrchestra BioMed$33.48M7.33N/AN/A$0.95 per share4.32PROFProfound Medical$16.10M14.96N/AN/A$1.83 per share3.62SGHTSight Sciences$77.36M3.61N/AN/A$1.21 per share4.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)OBIOOrchestra BioMed-$52.70M-$0.97N/AN/AN/A-166.96%-157.46%-60.18%8/11/2026 (Estimated)PROFProfound Medical-$42.57M-$1.24N/AN/AN/A-206.76%-78.88%-64.06%8/13/2026 (Estimated)SGHTSight Sciences-$38.43M-$0.71N/AN/AN/A-46.83%-52.34%-28.49%8/6/2026 (Estimated)Latest LNSR, SGHT, PROF, and OBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OBIOOrchestra BioMed-$0.40-$0.33+$0.07-$0.33$0.92 million$0.11 million5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 million5/7/2026Q1 2026PROFProfound Medical-$0.24-$0.19+$0.05-$0.19$4.85 million$5.34 million5/6/2026Q1 2026SGHTSight Sciences-$0.19-$0.24-$0.05-$0.24$18.47 million$19.70 million3/31/2026Q4 2025LNSRLENSAR-$0.10-$0.12-$0.02-$0.12$20.30 million$16.03 million3/12/2026Q4 2025OBIOOrchestra BioMed-$0.38$0.26+$0.64$0.26$0.93 million$30.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLNSRLENSARN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNSRLENSARN/A2.381.08OBIOOrchestra BioMed0.357.037.01PROFProfound MedicalN/A6.565.71SGHTSight Sciences0.685.865.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNSRLENSAR40.15%OBIOOrchestra BioMed53.20%PROFProfound Medical47.86%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipLNSRLENSAR66.00%OBIOOrchestra BioMed7.50%PROFProfound Medical1.52%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNSRLENSAR11012.10 million4.12 millionOptionableOBIOOrchestra BioMed459.88 million55.39 millionNot OptionablePROFProfound Medical15036.34 million35.79 millionOptionableSGHTSight Sciences21054.41 million37.60 millionOptionableLNSR, SGHT, PROF, and OBIO HeadlinesRecent News About These CompaniesSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2026 | marketbeat.comSight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 13, 2026 | seekingalpha.comSight Sciences Earnings Call Signals Disciplined GrowthMay 7, 2026 | tipranks.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comSight Sciences, Inc. (SGHT) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSight Sciences (SGHT) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesMay 6, 2026 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue EstimatesMay 6, 2026 | zacks.comSight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue GuidanceMay 6, 2026 | globenewswire.comSight Sciences to Present at Two Upcoming Investor ConferencesApril 29, 2026 | globenewswire.comSight Sciences Announces the Release of its Sustainability ReportApril 22, 2026 | markets.businessinsider.comSight Sciences Announces the Release of its Sustainability ReportApril 22, 2026 | globenewswire.comSight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026April 21, 2026 | globenewswire.comInsider Selling: Sight Sciences (NASDAQ:SGHT) CFO Sells 7,231 Shares of StockApril 10, 2026 | insidertrades.comInsider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells 2,869 Shares of StockApril 4, 2026 | insidertrades.comSight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and ...April 1, 2026 | finance.yahoo.comSight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingApril 1, 2026 | globenewswire.comSight Sciences secures $34M patent infringement win against AlconMarch 30, 2026 | massdevice.comSight Sciences wins $34M patent ruling against AlconMarch 30, 2026 | msn.comSight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13thMarch 30, 2026 | globenewswire.comSight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® MicrostentMarch 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRobinhood, SoFi, and Webull Are Telling Very Different StoriesBy Peter Frank | May 17, 2026TJX Companies Fires on All Cylinders With 9% Revenue GrowthBy Thomas Hughes | May 21, 2026GameStop’s $2 Billion Buyback Sends a Confusing Signal to InvestorsBy Thomas Hughes | June 10, 2026Dollar Tree Keeps Winning After Family Dollar DivorceBy Leo Miller | May 29, 2026Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026By Thomas Hughes | May 26, 2026LNSR, SGHT, PROF, and OBIO Company DescriptionsLENSAR NASDAQ:LNSR$5.82 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.84 +0.02 (+0.34%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Orchestra BioMed NASDAQ:OBIO$4.10 +0.03 (+0.74%) Closing price 04:00 PM EasternExtended Trading$4.10 0.00 (0.00%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Profound Medical NASDAQ:PROF$6.63 -0.02 (-0.30%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Sight Sciences NASDAQ:SGHT$5.13 +0.34 (+7.10%) Closing price 04:00 PM EasternExtended Trading$5.18 +0.05 (+1.07%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
